How much revenue does Caplin Point Laboratories make?

Caplin Point Laboratories reported 19.37 billion INR in revenue for fiscal year 2025, up 14.4% from 16.94 billion INR in fiscal year 2024. In Q1 2026 revenue was 5.10 billion INR.

Where does Caplin Point Laboratories make most of its revenue?

Rest of The World: 82% of revenue by region in fiscal year 2025, followed by United States of America (18%).

What companies are similar to Caplin Point Laboratories?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Emcure Pharmaceuticals L (EMCURE.NS), Wockhardt Limited (WOCKPHARMA.NS), Granules India Limited (GRANULES.NS), Pfizer Limited (PFIZER.NS).

Caplin Point Laboratories Limited (CAPLIPOINT.NS) Stock

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infu...

At a glance

Caplin Point Laboratories reported revenue of 19.37 billion INR for fiscal year 2025, up 14.4% from fiscal year 2024, and net income of 5.36 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 5.10 billion INR, up 11.2% from a year before. Rest of The World was its largest region in fiscal year 2025, with 82% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.